Why Does Every Hepatocellular Carcinoma Clinical Trial Using Molecular Targeted Agents Fail?

Publisher： Karger

E-ISSN： 1664-5553|1|2|59-60

ISSN： 2235-1795

Source： Liver Cancer, Vol.1, Iss.2, 2012-09, pp. : 59-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives

By  

Liver Cancer, Vol. 6, Iss. 2, 2016-12 ,pp. : 101-112

Karger

Access to resources Recommend Favorite

Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 29, Iss. 3, 2011-08 ,pp. : 289-302

Karger

Access to resources Recommend Favorite

Molecular Targeted Therapy for Hepatocellular Carcinoma: Bench to Bedside

By  

Digestive Diseases, Vol. 29, Iss. 3, 2011-08 ,pp. : 273-277

Karger

Access to resources Recommend Favorite

Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future

By  

Liver Cancer, Vol. 3, Iss. 1, 2014-02 ,pp. : 9-17

Karger

Access to resources Recommend Favorite

Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives

By Shen Ying-Chun   Hsu Chiun   Cheng Ann-Lii  

Journal of Gastroenterology, Vol. 45, Iss. 8, 2010-08 ,pp. : 794-807

Springer Publishing Company

Access to resources Recommend Favorite